MX2009003125A - Tiazol pirazolopirimidinas como antagonistas de receptor de crf1. - Google Patents

Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.

Info

Publication number
MX2009003125A
MX2009003125A MX2009003125A MX2009003125A MX2009003125A MX 2009003125 A MX2009003125 A MX 2009003125A MX 2009003125 A MX2009003125 A MX 2009003125A MX 2009003125 A MX2009003125 A MX 2009003125A MX 2009003125 A MX2009003125 A MX 2009003125A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
crf1 receptor
pyrazolopyrimidines
thiazole
crf1
Prior art date
Application number
MX2009003125A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Takako Takakuwa
Jason Kenneth Myers
Erik James Hembre
Zhaogen Chen
James Lee Toth
Chafiq Hamdouchi Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003125(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009003125A publication Critical patent/MX2009003125A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a compuestos de Fórmula I, composiciones farmacéuticas de los mismos, y uso de tales compuestos como antagonistas de receptor de factor 1 liberador de corticotropina (CRF1) en el tratamiento de desórdenes psiquiátricos y neuroendocrinos, enfermedades neurológicas y síndrome metabólico. (ver fórmula (I)).
MX2009003125A 2006-09-20 2007-09-17 Tiazol pirazolopirimidinas como antagonistas de receptor de crf1. MX2009003125A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20
PCT/US2007/078605 WO2008036579A1 (en) 2006-09-20 2007-09-17 Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009003125A true MX2009003125A (es) 2009-05-28

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003125A MX2009003125A (es) 2006-09-20 2007-09-17 Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.

Country Status (34)

Country Link
US (1) US8030304B2 (es)
EP (1) EP2094709B1 (es)
JP (1) JP5161226B2 (es)
KR (1) KR101088239B1 (es)
CN (1) CN101516887B (es)
AR (1) AR062886A1 (es)
AT (1) ATE481405T1 (es)
AU (1) AU2007297421B2 (es)
BR (1) BRPI0717023B8 (es)
CA (1) CA2663511C (es)
CL (1) CL2007002693A1 (es)
CR (1) CR10682A (es)
CY (1) CY1110854T1 (es)
DE (1) DE602007009305D1 (es)
DK (1) DK2094709T3 (es)
EA (1) EA015179B1 (es)
ES (1) ES2350282T3 (es)
HK (1) HK1132505A1 (es)
HR (1) HRP20100516T1 (es)
IL (1) IL197614A (es)
MA (1) MA30798B1 (es)
MX (1) MX2009003125A (es)
MY (1) MY146388A (es)
NO (1) NO20091489L (es)
NZ (1) NZ575572A (es)
PE (1) PE20081377A1 (es)
PL (1) PL2094709T3 (es)
PT (1) PT2094709E (es)
RS (1) RS51545B (es)
SI (1) SI2094709T1 (es)
TN (1) TN2009000095A1 (es)
TW (1) TWI402269B (es)
UA (1) UA96458C2 (es)
WO (1) WO2008036579A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2009298757B2 (en) * 2008-10-02 2013-08-01 Eli Lilly And Company Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA3155599A1 (en) * 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CA3039026A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
WO2019036503A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
AU2018318990B2 (en) * 2017-08-14 2023-01-05 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
CA3098562A1 (en) * 2018-04-27 2019-10-31 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
EP4069697A1 (en) * 2019-12-04 2022-10-12 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
KR20230043222A (ko) * 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023091684A1 (en) * 2021-11-19 2023-05-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013676A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
CN1090189C (zh) * 1996-02-07 2002-09-04 詹森药业有限公司 吡唑并嘧啶类化合物
NZ333777A (en) * 1996-07-24 2000-07-28 Du Pont Pharm Co (1,5-a) pyrazolo and triazole triazines and pyrimidines
ES2294800T3 (es) * 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CZ20021089A3 (cs) 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
MXPA03008185A (es) * 2001-03-13 2004-01-29 Bristol Myers Squibb Pharma Co 4-(2-butilamino)-2, 7-dimetil-8 -(2-metil-6-metoxipirid -3-il) pirazol-[1, 5-a]-1, 3, 5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor de liberacion de corticotropina.
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto

Also Published As

Publication number Publication date
ES2350282T3 (es) 2011-01-20
RS51545B (en) 2011-06-30
JP2010504344A (ja) 2010-02-12
EA200970303A1 (ru) 2009-10-30
PT2094709E (pt) 2010-10-04
PL2094709T3 (pl) 2011-02-28
MY146388A (en) 2012-08-15
TN2009000095A1 (en) 2010-08-19
EA015179B1 (ru) 2011-06-30
HK1132505A1 (en) 2010-02-26
BRPI0717023A2 (pt) 2014-03-11
IL197614A0 (en) 2009-12-24
AU2007297421B2 (en) 2012-03-08
BRPI0717023B8 (pt) 2021-05-25
EP2094709A1 (en) 2009-09-02
HRP20100516T1 (hr) 2010-10-31
CR10682A (es) 2009-08-13
AR062886A1 (es) 2008-12-10
WO2008036579A1 (en) 2008-03-27
CA2663511C (en) 2012-12-04
PE20081377A1 (es) 2008-09-18
US8030304B2 (en) 2011-10-04
US20100222339A1 (en) 2010-09-02
KR101088239B1 (ko) 2011-11-30
UA96458C2 (ru) 2011-11-10
AU2007297421A1 (en) 2008-03-27
NO20091489L (no) 2009-04-16
DK2094709T3 (da) 2010-12-06
BRPI0717023B1 (pt) 2019-11-19
NZ575572A (en) 2011-10-28
CY1110854T1 (el) 2015-06-10
EP2094709B1 (en) 2010-09-15
IL197614A (en) 2012-10-31
CA2663511A1 (en) 2008-03-27
DE602007009305D1 (de) 2010-10-28
SI2094709T1 (sl) 2011-01-31
TW200821312A (en) 2008-05-16
KR20090052366A (ko) 2009-05-25
MA30798B1 (fr) 2009-10-01
JP5161226B2 (ja) 2013-03-13
TWI402269B (zh) 2013-07-21
ATE481405T1 (de) 2010-10-15
CL2007002693A1 (es) 2008-04-18
CN101516887B (zh) 2011-11-02
CN101516887A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
UA96458C2 (ru) Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
MX2009003098A (es) Compuestos de tiofen pirazolopirimidina.
CY1109069T1 (el) Ενωσεις ιμιδαζοπυριδαζινης
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
GB0625648D0 (en) Compounds
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
PL2049529T3 (pl) Podstawione związki diazepanowe - antagoniści receptora oreksyny
GEP20104962B (en) Fused heterocyclic compounds
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
WO2008045564A3 (en) Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
EA200800264A1 (ru) Производные пиразоло[3,4-d]азепина как антагонисты н3-рецепторов гистамина
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
TW200734324A (en) Therapeutic agents
DE602007007934D1 (en) Imidazoazephinonverbindungen
WO2006138589A3 (en) Opioid receptor ligands

Legal Events

Date Code Title Description
FG Grant or registration